{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:57:41Z","timestamp":1787785061940,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2022.01.034","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T22:00:22Z","timestamp":1643925622000},"page":"1271-1281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant\/delivery system"],"prefix":"10.1016","volume":"40","author":[{"given":"Geoffrey J.","family":"Gorse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Mulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-5924","authenticated-orcid":false,"given":"Peter","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.vaccine.2022.01.034_b0005","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2009.06.057","article-title":"Safety and immunogenicity of a subvirion inactivated influenza A\/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults","volume":"27","author":"Brady","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.034_b0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0264-410X(93)90190-9","article-title":"Adjuvants \u2013 a balance between toxicity and adjuvanticity","volume":"11","author":"Gupta","year":"1993","journal-title":"Vaccine"},{"issue":"17-19","key":"10.1016\/j.vaccine.2022.01.034_b0015","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","article-title":"The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59\u2013adjuvanted vaccine","volume":"19","author":"Podda","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.034_b0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1017919305501","article-title":"Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared t a conventional subunit vaccine in elderly subjects","volume":"17","author":"Gasparini","year":"2001","journal-title":"Eur J Epidemiol"},{"issue":"11-12","key":"10.1016\/j.vaccine.2022.01.034_b0025","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0264-410X(02)00401-2","article-title":"Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects","volume":"21","author":"Squarcione","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.034_b0030","doi-asserted-by":"crossref","first-page":"e11995","DOI":"10.1371\/journal.pone.0011995","article-title":"Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity","volume":"5","author":"Graham","year":"2010","journal-title":"PLoS ONE"},{"issue":"41","key":"10.1016\/j.vaccine.2022.01.034_b0035","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1016\/j.vaccine.2005.05.036","article-title":"Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques","volume":"23","author":"Langermans","year":"2005","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.034_b0040","doi-asserted-by":"crossref","first-page":"e3960","DOI":"10.1371\/journal.pone.0003960","article-title":"Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel\u2122, Montanide ISA 720 or AS02","volume":"3","author":"Roestenberg","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.01.034_b0045","series-title":"Diagnostic procedures for viral, rickettsial, and chlamydial infections","first-page":"431","article-title":"Influenza","author":"Couch","year":"1995"},{"key":"10.1016\/j.vaccine.2022.01.034_b0050","article-title":"Concepts and procedures for laboratory based influenza surveillance. Atlanta: World Health Organization Collaborating Centers for Reference and Research in Influenza, Centers for Disease","author":"Kendal","year":"1982","journal-title":"Control"},{"key":"10.1016\/j.vaccine.2022.01.034_b0055","doi-asserted-by":"crossref","unstructured":"Ohmit, SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204: 1879-85.","DOI":"10.1093\/infdis\/jir661"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.034_b0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/421121","article-title":"Peduzzi PN Immunity to influenza in older adults with chronic obstructive pulmonary disease","volume":"190","author":"Gorse","year":"2004","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.034_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/CVI.00604-15","article-title":"Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial","volume":"23","author":"Dunning","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.034_b0070","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A\/H3N2 influenza disease. Open Forum","volume":"2","author":"Benoit","year":"2015","journal-title":"Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.034_b0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.01.034_b0080","doi-asserted-by":"crossref","unstructured":"Cowling BJ., Lim WW, Perera RAPM, Fang VJ, Gabriel M Leung GM, J S Malik Peiris, et al. Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B. Clin Infect Dis 2019; 68:1713-7. doi: 10.1093\/cid\/ciy759","DOI":"10.1093\/cid\/ciy759"},{"key":"10.1016\/j.vaccine.2022.01.034_b0085","doi-asserted-by":"crossref","unstructured":"Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model. mBio 2016; 7:e00417-16. doi:10.1128\/mBio.00417-16:e00417-16.","DOI":"10.1128\/mBio.00417-16"},{"issue":"45","key":"10.1016\/j.vaccine.2022.01.034_b0090","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1016\/j.vaccine.2017.09.036","article-title":"Association between haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015","volume":"35","author":"Ng","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.034_b0095","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.vaccine.2019.01.055","article-title":"Evaluation of correlates of protection against influenza A (H3N2) and A (H1N1)pdm09 infection: Applications to the hospitalized patient population","volume":"37","author":"Petrie","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.034_b0100","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiu186","article-title":"Association between antibody titers and protection against influenza virus infection within households","volume":"210","author":"Tsang","year":"2014","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.034_b0105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/infdis\/jiu187","article-title":"Influenza vaccine in the red zone defense: a game-day player","volume":"210","author":"Peters","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.034_b0110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/14760584.3.6.643","article-title":"Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine","volume":"3","author":"Belshe","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2022.01.034_b0115","doi-asserted-by":"crossref","first-page":"D5","DOI":"10.1016\/j.vaccine.2008.05.076","article-title":"Seasonal Inactivated Influenza Virus Vaccines","volume":"26","author":"Couch","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.034_b0120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.vaccine.2011.10.061","article-title":"Antibody response to the influenza vaccine in healthcare workers","volume":"30","author":"Sacadura-Leite","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.034_b0125","doi-asserted-by":"crossref","unstructured":"Trieu MC, Jul-Larsen A, S\u00e6vik M, Madsen A, N\u00f8stbakken JK, Zhou F, et al. Antibody responses to influenza A\/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-Year Follow-up Study. Clin Infect Dis 2019; 68:382\u201392. DOI: 10.1093\/cid\/ciy487","DOI":"10.1093\/cid\/ciy487"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.034_b0130","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/infdis\/jiv313","article-title":"Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination","volume":"212","author":"Petrie","year":"2015","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.034_b0135","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/524146","article-title":"Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?","volume":"197","author":"Skowronski","year":"2008","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.01.034_b0140","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.4161\/hv.25580","article-title":"Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Results of a randomized, controlled comparison","volume":"9","author":"Scheifele","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2022.01.034_b0145","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/S0264-410X(03)00456-0","article-title":"Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults","volume":"21","author":"Frey","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.034_b0150","doi-asserted-by":"crossref","unstructured":"El Sahly H. MF59\u2122 as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 2010; 9:1135-41. Doi.org\/10.1586\/erv.10.111","DOI":"10.1586\/erv.10.111"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.034_b0155","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.01.034_b0160","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/irv.12245","article-title":"Influenza symptoms and their impact on elderly adults: randomized trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines","volume":"8","author":"Van Essen","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"issue":"37","key":"10.1016\/j.vaccine.2022.01.034_b0165","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1016\/j.vaccine.2009.06.032","article-title":"Influenza control in the 21st century: Optimizing protection of older adults","volume":"27","author":"Monto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.034_b0170","first-page":"191","article-title":"Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in the elderly","volume":"32","author":"Reef","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2022.01.034_b0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.vaccine.2007.10.051","article-title":"Antibody induction by virosomal M59-adjuvanted, or conventional influenza vaccines in the elderly","volume":"26","author":"de Bruijn","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.034_b0180","doi-asserted-by":"crossref","unstructured":"Madsen A, Jul-Larsen A, Trieu M-C, Krammer F, Cox RJ. Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody Response. npj Vaccines 2021; 6:45. doi.org\/10.1038\/s41541-021-00308-5","DOI":"10.1038\/s41541-021-00308-5"},{"key":"10.1016\/j.vaccine.2022.01.034_b0185","first-page":"337","article-title":"GSK\u2019s novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection","volume":"11","author":"Jones","year":"2009","journal-title":"Curr Opinion Molec Therapeut"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.034_b0190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1054\/bjoc.2000.1315","article-title":"Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer","volume":"83","author":"Simms","year":"2000","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2022.01.034_b0195","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.21814","article-title":"An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated advanced gastric or gastroesophageal cancer: the GC4 study","volume":"106","author":"Ajani","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.034_b0200","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/08916934.2014.910768","article-title":"MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice","volume":"47","author":"Zhang","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.vaccine.2022.01.034_b0205","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","article-title":"MER5101, a novel A\u03b21-15:DT conjugate vaccine, generates a robust anti-A\u03b2 antibody response and attenuates A\u03b2 pathology and cognitive deficits in APPswe\/PS11\u0394E9 transgenic mice","volume":"33","author":"Liu","year":"2013","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.034_b0210","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/irv.12031","article-title":"Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy","volume":"7","author":"Fox","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2022.01.034_b0215","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0264-410X(02)00748-X","article-title":"Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study","volume":"21","author":"Gorse","year":"2003","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2022.01.034_b0220","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.034_b0225","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.vaccine.2009.04.078","article-title":"Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B\/Victoria and B\/Yamagata lineages","volume":"27","author":"Camilloni","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.034_b0230","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1128\/CVI.00615-13","article-title":"Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly","volume":"21","author":"Seo","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.01.034_b0235","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s15010-004-3204-z","article-title":"Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly","volume":"32","author":"Ruf","year":"2004","journal-title":"Infection"},{"issue":"23-24","key":"10.1016\/j.vaccine.2022.01.034_b0240","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"issue":"7827","key":"10.1016\/j.vaccine.2022.01.034_b0245","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2711-0","article-title":"Human germinal centres engage memory and naive B cells after influenza vaccination","volume":"586","author":"Turner","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.01.034_b0111","doi-asserted-by":"crossref","unstructured":"Gorse GJ, Stephen G, Buck H, Mulla H, White P, Hill H, May J, Frey SE, Blackburn P. MAS-1, a novel water-in-oil adjuvant\/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. 2022 (in press). https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.035.","DOI":"10.1016\/j.vaccine.2022.01.035"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:08:47Z","timestamp":1759403327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000585"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant\/delivery system","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}